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Summary To assess the role of insulin-like growth factors (IGFs) in growth and transformation of normal (myometrium) and tumorous smooth
muscle cell (SMC) tissues, in situ hybridization (ISH) analysis for insulin-like growth factor and 11 (IGF-I and IGF-Il) mRNAs was combined
with detection of IGF peptides, their receptors and IGF binding protein-3 (IGFBP-3). mRNAs for both IGFs were detected in smooth muscle
cells in normal, benign and malignant SMC tissues, together with the IGF peptides, both IGF receptors and IGFBP-3. This suggests an
autocrine role for both IGFs. Leiomyomas had higher IGF-I peptide levels and higher levels of type I IGF receptors than myometrium,
supporting the idea that IGFs play a role in the growth and transformation of these tumours. Low-grade leiomyosarcomas contained more
IGF-Il mRNAs than myometrium and leiomyoma, fewertype 11 IGF/mannose 6-phosphate receptors and less IGFBP-3 than myometrium and,
in addition, fewer IGF-I mRNAs and type I IGF receptors than leiomyoma. Intermediate- and high-grade leiomyosarcomas had intermediate
levels of IGF-Il mRNAs and peptide, ranging between those in myometrium and low-grade leiomyosarcomas. Thus, growth and transformation
of leiomyosarcomas may be regulated by IGF-11, although more markedly in low-grade than in high-grade leiomyosarcomas. In conclusion, the
various categories of SMC tissues are associated with a distinct expression pattern of the IGF system. This suggests that each category of
SMC tumours arises as a distinct entity and that there is no progression of transformation in these tissues.
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Transformation is a stepwise process in which cells proceed to a
different phenotype because of genomic alterations. At the func-
tional level, the transformed phenotype is characterized by one or
more of the following features: immortalization, change in cell
morphology, in vitro focus formation due to decreased contact
inhibition, reduced in vitro requirement of serum growth factors,
anchorage-independent growth (growth in soft agar) and in vivo
tumorigenicity (Wharton and Smyth, 1989). Transformation
requires the activation of specific transformation signalling path-
ways. This is illustrated by the observation that type I insulin-like
growth factor receptor-deficient fibroblasts, which have impaired
growth capacity, acquire a transformed phenotype after transfec-
tion with ras, without reversal ofthe growth deficiencies (Baserga
et al, 1994; Sell et al, 1994). Thus, transformation is independent
of increased cell proliferation, although unrestricted proliferation
may be favoured with progressing transformation. Similarly,
apoptosis and transformation are independent functions, although
the apoptosis-inducing pathway may be blocked by the accumu-
lation of genomic alterations, e.g. by the activation of the
apoptosis blocking oncogene bc12 (Aaronson, 1991; Schmandt
and Mills, 1993).
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Initiation oftransformation may result from deregulated activity
of any factor in transformation signalling pathways and thus may
involve overstimulation with growth factors, enhanced receptor
signalling and increased activity of second messengers and of
nuclear binding proteins. Transforming growth factor x and ,
and platelet-derived growth factor BB are typical inducers of
transformation in selected systems (Burgess, 1989; Heldin and
Westermark, 1989; Hsuan, 1989). In addition, transformation may
result from decreased activity oftransformation-inhibiting factors,
known as products of anti-oncogenes or tumour-suppressor genes
(Schmandt and Mills, 1993).
The insulin-like growth factors (IGF-I and IGF-II) are polypep-
tide growth factors, which play an important role in cellular and
somatic growth (Cohick and Clemmons, 1993). Both IGFs can
bind to the type I IGF receptor with similar affinity, whereas the
type II IGF/mannose 6-phosphate receptor preferentially binds
IGF-II. The type I IGF receptor mediates the mitogenic action of
both IGFs (Nissley and Lopaczynski, 1991), and the type II IGF
receptor is mainly associated with differentiation and histomorpho-
genesis (Nissley and Lopaczynski, 1991). IGFfunctions are modu-
lated by IGF-binding proteins (IGFBPs), of which six distinct
variants have been characterized (Drop et al, 1992). At the cellular
level, these IGFBPs may facilitate the binding of IGFs to their
receptors or they may inhibit this binding (Jones and Clemmons,
1995). Although IGFs are not designated as (proto)oncogene prod-
ucts, there are many indications that they have transformation-
inducing capacity. For instance, overexpression of the IGFs or of
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the type I IGF receptor is observed in many human tumours (Glick
et al, 1989; Tommola et al, 1989; Merrill and Edwards, 1990;
Macaulay, 1992).
We have previously shown that higher IGF-I concentrations in
leiomyoma than in myometrium may be as a result of the higher
levels of type I IGF receptors in leiomyoma (Van der Ven et al,
1994). The increased responsiveness to IGF-I of cultured
leiomyoma smooth muscle cells compared with theirnormal coun-
terparts is in line with this observation. Furthermore, malignant
transformation of smooth muscle tissues is associated with
increased expression of IGF-II (Gloudemans et al, 1990). In the
present study, employing in situ hybridization for IGF-I mRNA,
we analyse whether the increased levels of IGF-I in benign
compared with normal smooth muscle cells could be of autocrine
source. This series is completed with an analysis of malignant
smooth muscle tissues. In these tissues, we also compare IGF-II
mRNA hybridization signal, IGF-I and -II peptide concentrations,
immunohistochemical localizations and staining intensities, and
immunohistochemistry of both IGF receptors and of IGFBP-3 to
find indications for a role of the IGF system during oncogenic
transformation in these tissues.
MATERIALS AND METHODS
Tissue collection
Normal and benign smooth muscle tissues were obtained from the
uteri of patients that had undergone hysterectomy to treat
leiomyoma. Informed consent was obtained according to the
guidelines ofthe Dutch CancerFoundation and the Ethical Council
of the Utrecht University Hospital. Leiomyosarcomas were
resected from a variety of organs. Specimens were collected from
surgery as soon as possible. Part of the tissue was snap-frozen in
liquid nitrogen and stored at -80°C for further use in mRNA or
peptide extraction procedures and for immunohistochemistry.
Another part was routinely fixed in 4% phosphate-buffered
formaldehyde (Klinipath, Duiven, The Netherlands), dehydrated
through a graded ethanol/xylene series and embedded in paraffin.
Data of the tissues that were included in this analysis are outlined
in the Table. Most ofthe included tissues show positive staining for
x-smooth muscle actin or desmin, confirming the smooth muscle
phenotype. Loss of expression of smooth muscle markers in
leiomyosarcomas is a common event in these tumours (Roholl et
al, 1990). The shown percentage of necrosis was estimated on
histological sections. A high necrotic index would bias the results
from radioimmunoassays. Therefore, tumours with a high
percentage of necrosis (>50%) were excluded from assays in
which vitality of the tissue could not be checked. The protocol for
use ofthe tissues in this study was approved by the Ethical Council
ofthe Utrecht University Hospital.
Northern blotting analysis
The presented Northern blotting data are a revision of previous
results (Gloudemans et al, 1990). The original films were scanned
in a densitometer, and scanning values of7.6-kb IGF-I mRNA and
of 4.8- and 6.0-kb IGF-II mRNA bands were corrected for expos-
ure time. The Northern blotting analysis comprises the same tissue
cohort, although more samples were processed for Northern blot-
ting than for in situ hybridization. In the present analysis, the
quantified Northern blotting results are rearranged according to
the classification shown in the Table.
In situ hybridization
From the paraffinized tissues, 4-,im sections were prepared on
aminopropyltriethoxysilane (Sigma Chemicals, St Louis, MO,
USA) coated slides. Specific mRNAs were detected by subjecting
the sections to an in situ hybridization procedure (Denijn et al,
Table Clinical data and characteristics of tissues
Code Sex, age Site of resection Tissue Smooth muscle markersa Necrosis (%)
(years)
a-SMA Desmin
Normal myometrium (MM) and leiomyoma (LM)
A-G F, 38-50 Uterus Normal MM, LM All ++ 0
Leiomyosarcoma Grading'
A M, 27 Oesophagus Low ++ 0
B M, 69 Stomach Low - + 0
C M, 78 Stomach Low + - <10
D F, 73 Stomach Low ++ <10
E M, 32 Retroperitoneal Low ++ < 5
Fac F, 34 Mesenteric lymph node Low - + 0
Fb F, 38 Abdominal wall metastasis Low + + <10
G M,41 Mesenterium Intermediate + + <10
H M, 82 Subcutis (left arm) Intermediate ++ + 10-50
M, 55 Retroperitoneal Intermediate + > 50
J M, 69 Right axilla Intermediate + + > 50
K F, 70 M. quadriceps femoris Intermediate <10
Lad F, 53 Retroperitoneum (recurrence) High ++ 10-50
Lb F, 53 Retroperitoneum (recurrence) High > 50
aAdditional phenotyping was done with immunohistochemical staining for the smooth muscle markers a-SMA and desmin, which are scored in a range
from -, no staining to ++, high-intensity staining. Blanks in the 'desmin' column are not tested. bLeiomyosarcomas were graded according to the number
of mitoses per mm2 (< 3, low grade; 4-25, intermediate grade; and > 25, high grade) and are arranged with increasing mitotic index. cTumours Fa and Fb
originated from the same patient with an interval of 3.5 years. dTumours La and Lb originated from the same patient with an interval of 8.5 months.
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1990; Wilkinson and Green, 1992) with antisense RNA probes for
IGF-I and IGF-II. These were prepared from cDNA of IGF-I
(pIGF-I, exons 1, 3 and 4; 777 base pairs; Jansen et al, 1983) and
cDNA of IGF-II (pIGF-Ilvar, exons 3, 7, 8 and 9; 713 base pairs;
Jansen M et al, 1990), cloned in the vector pBluescript-KS
(Stratagene, La Jolla, CA, USA) and reverse transcribed with T3
RNA polymerase (Boehringer, Mannheim, Germany) in the pres-
ence of [35S]UTP (Amersham, Amersham, UK). Specificity of
these probes was tested in tissue sections from mice transgenic for
human IGF-II (Van Buul-Offers et al, 1995) and, furthermore,
IGF-I and IGF-II hybridization signals were compared with the
signal of a thrombin receptor probe on smooth muscle tissue
sections. Briefly, the in situ hybridization procedure includes
dewaxing, rehydration, permeabilization in Triton X-100
(Boehringer), treatment with 50 ,ug ml-1 proteinase K
(Boehringer), acetylation and dehydration of the sections. Control
sections were subjected to a RNAase treatment (100 jg ml-'
RNAase A and 1 jg ml-l RNAase TI; both from Boehringer) to
degrade the hybridization target. Labelled probe in a concentration
of 200 000 c.p.m. per 30 jl ofhybridization buffer was incubated
with the sections overnight at 55'C and, after several washing
steps, sections were dehydrated in a series of ethanol containing
0.3 M ammonium acetate, air-dried and exposed to a storage phos-
phor screen (Molecular Dynamics) for 8-18 h, depending on the
signal intensity. This screen was scanned with a Phosphor Imager
(Molecular Dynamics), and the signal of a representative, stan-
dardized surface of approximately 0.4 cm2 was quantified. Data
from individual sections were transformed to a percentage relative
to the mean ofthe four scanned myometrium sections.
Immunohistochemistry
Tissue cryosections of 6 jim were prepared with a microtome-
cryostat (Damon IEC, Needham, MA, USA) on gelatin-coated
slides and air-dried. These sections were fixed with paraformalde-
hyde (Merck, Darmstadt, Germany) and subjected to an immuno-
cytochemical procedure with specific polyclonal antisera for
human IGF-I (batches no. 874 diluted 1:150 and no. 878/4 diluted
1:250, which were kind gifts from Dr BH Breier, Auckland, New
Zealand); for human IGF-II (batches no. C41 and no. C65, diluted
1:200, also obtained from Drs BH Breier and PD Gluckman; and
batch no. 12/2378, diluted 1:100, a kind gift of Dr J Zapf, Zurich,
Switzerland); for the human type I IGF receptor, diluted 1:100 (a
kind gift ofDr SA Rosenzweig, New Haven, CO, USA); forthe rat
type II IGF/M6P receptor, diluted 1:2000 (batch no. 3637, a kind
gift of Dr SP Nissley, Bethesda, MD, USA); for human IGFBP-3,
batch no. 3596, diluted 1:1000 (a generous gift of Dr J Van Doom,
Utrecht, The Netherlands); and monoclonal antibodies for the
human type I IGF receptor, dilution 1:25 (a-IR3; Oncogene
Science, Manhassat, NY, USA); for a-smooth muscle actin, dilu-
tion 1:400 (a-SMA, Sigma); and a polyclonal antiserum for
desmin (Eurodiagnostics, Apeldoorn, The Netherlands). The last
two antibodies were included as independent phenotypic markers.
Antisera no. 878/4 and no. C65 were characterized for use in
immunohistochemistry by Klempt et al (1992); specificity for
immunostaining ofthe polyclonal antisera forthe type I and type II
IGF receptors was demonstrated by Rosenzweig et al (1990)
and by Couce et al (1992) respectively. The no. 3637 antiserum
cross-reacts with the human type II IGF receptor (Gelato et al,
1988). The IGFBP-3 antiserum recognizes the IGFBP-3
38.5-41.5-kDa bands and IGFBP-3 degradation products in an
immunoblotting of human serum, but not IGFBP-2 and -4. In a
radioimmunoassay, there is no cross-reactivity of the IGFBP-3
antiserum to IGFBP-1. Binding of IGFs to IGFBP-3 does not
interfere with binding ofthe antiserum to IGFBP-3 (Bruning et al,
1995). Preincubation of the IGFBP-3 antiserum with its antigen
induced a reduction of immunostaining intensity of 50-90% in
various normal and transformed smooth muscle tissues.
Background staining was checked by omitting the primary anti-
body. The immunohistochemical procedure was described else-
where (Van der Ven et al, 1994) and includes preincubation with a
normal serum, analogous to the species origin of the second anti-
body, incubation with the primary antibody and an appropriate
biotinylated second antibody (together with the normal sera
obtained from Vector, Burlingame, CA, USA). These steps were
alternated with washes with phosphate-buffered saline
(PBS)/Tween. The bound immune complex was visualized with
horseradish peroxidase-avidin-biotin complex (Vector). As a
chromogenic substrate for the horseradish peroxidase, we used
nickel-enhanced 3,3'diaminobenzidine (DAB, Merck). Nuclei
were counterstained with nuclear fast red. Immunostained cells
were dehydrated in ethanol/xylene and embedded in DePeX.
Immunostained sections were examined by two independent
observers for staining pattern (appearance and localization) and for
staining intensity. Each independent antibody was scored subjec-
tively in a range including absent or low (±), intermediate (+) and
high (++) staining intensity. For each variable, results from dupli-
cate observations with either the same or different antisera were
pooled.
Radioimmunoassay (RIA)
For determination of IGF-I and IGF-II concentrations in the
smooth muscle tissues, tissue extracts were prepared as described
previously (D'Ercole and Underwood, 1987; Van der Ven et al,
1994). IGF-binding proteins were eliminated from these extracts
under acid conditions using C18 Sep-Pak cartridges (Sep-Pak,
Waters, Milford, MA, USA; Van der Ven et al, 1994), and IGFs
were measured in a radioimmunoassay as described previously
(Jansen J et al, 1990; Van Buul-Offers et al, 1994; Van der Ven et
al, 1994). The results were expressed in ng ml-', using recombi-
nant IGF-I (International Reference Reagent 87/518 from the
National Institute for Biological Standards and Control, Potters
Bar, Herts, UK) and native human IGF-II extracted in our own
laboratory (Van den Brande et al, 1990) as the reference peptides
respectively. For the IGF-I RIA, the intra- and interassay coeffi-
cients of variation were 5.9% and 7.9%, and for the IGF-II RIA
these values were 7.0% and 7.7% (Bruning et al, 1995). The lower
detection limit was 0.005 ng per tube for IGF-I and 0.014 ng per
tube for IGF-II.
Statistical analysis
Differences of levels of mRNAs and peptides of IGF-I and IGF-II
among the four categories of tissues (normal, benign, low-grade
malignant and intermediate-high-grade malignant) were tested for
significance using a Student's t-test or in a Welch t-test when vari-
ances between groups departed significantly from homogeneity.
Significance of difference of the observed distribution from a
random distribution ofimmunohistochemical staining intensities for
IGF-I, IGF-II, both IGF receptors or IGFBP-3 over the four cate-
gories ofsmooth muscle tissues was analysed in a chi-square test.
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Figure 1 Overview of the distribution of in situ hybridization signal for IGF-11 mRNA in smooth muscle tissues, viewed with darkfield microscopy. The white
signal indicates the presence of IGF-11 mRNA. Sections hybridized with [35S]UTP-labelled probe were dipped in a liquid photographic emulsion. After
development, the resulting silver grains were visualized with dark-field imaging. Scale bar = 250gm. (A) Left, typical whirling pattern with local differences of
signal intensity in myometrium; right, characteristic uniform pattern in leiomyoma (B)IGF-11 mRNA signal in low-grade leiomyosarcomas, illustrating a uniform
hybridization pattern (left, case Fa in the Table) and a spot-wise pattern with regional intensity differences (right, case Fb in the Table)
RESULTS
Localization and quantification of IGF-I and IGF-II
mRNA
In situ hybridization showed that in myometrium both IGF-I and
IGF-II mRNAs are distributed in a whirling pattern, whereas the
distribution in leiomyoma shows a more uniform pattern. This
difference, illustrated for IGF-II in Figure IA, corresponds with
the histology of these tissues. In leiomyosarcomas, the pattern of
distribution is more variable. In Figure IB, both a diffuse distribu-
tion and a contrasting spot-wise signal distribution with regional
intensity differences are illustrated. At higher magnification the
signals for both IGF-I and IGF-II mRNAs emerge predominantly
from smooth muscle cells (illustrated for IGF-II in Figure 2). A
distinct difference between myometrium and leiomyoma is that
the signal is uniformly distributed over all cells in the former
tissue, whereas there are cell-dependent differences in signal
intensity in the latter. The leiomyosarcoma in Figure 2C illustrates
a high-intensity hybridization signal for IGF-II mRNA in smooth
muscle cells.
Using a phosphor imager, the hybridization signal was quanti-
fied. At the level of IGF-I mRNA there are no differences among
the four groups of tissues (Figure 3A). In situ hybridization for
IGF-II mRNAs, however, shows significantly higherlevels in low-
grade leiomyosarcomas than in myometrium and leiomyoma.
However, there were no higher IGF-ll mRNA levels in interme-
diate-high-grade tumours, compared with normal myometrium or
with low-grade tumours. The intensities of the hybridization
signals show large variations between individual leiomyosar-
comas, and these variations are different for IGF-I and IGF-II (not
shown). This indicates the specificity ofthese respective signals.
In the present analysis, previously prepared Northem blottings
are quantified and reclassified (see Materials and methods and
Gloudemans et al, 1990). Compared with the in situ hybridization
signals (Figure 3A), Northern blotting quantification confirms that
IGF-I mRNA levels are low in all four categories of tissues and
that IGF-II mRNA levels are higher in benign and malignant
tumours than in normal smooth muscle tissues, with maximal
expression in low-grade leiomyosarcomas. Statistical analysis
showed a significantly lower level of IGF-I mRNA in low-grade
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leiomyosarcomas than in leiomyomas. The higher IGF-11 mRNA
abundance is only significant in low-grade leiomyosarcomas,
compared withmyometrium.
Detection of IGFs and related proteins
Immunohistochemistry was used to detect the presence of IGF-I
protein in myometrium, leiomyoma and leiomyosarcoma. In the
cytoplasm of smooth muscle cells, staining was diffuse with
moderate intensity, whereas intense staining was found in the
nucleus, whichcouldbe diff-use ordotted(Figure4A). This nuclear
staining is unexplained. Results with both IGF-I antisera were
similar. Staining intensities werehigh in the cellularcompartments
ofmyometrium andleiomyoma and lower in the cellular compart-
ments ofmostleiomyosarcomas(Figure3B),representing asignif-
icantly asymmetrical distribution. Tissue concentrations of IGF-1,
as determined by a radioimmunoassay, are summarized in Figure
3A. Mean IGF-I concentration in leiomyomas was significantly
higherthan inmyometrium(not observed with immunohistochem-
istry). The variance of values in both groups ofleiomyosarcomas
was toohigh to detectsignificant differences.
There is an inconsistency between changes in IGF-I levels as
detected withradioimmunoassay and withimmunohistochemistry.
This may result from the fact that total tissue IGF-I concentrations
(radioimmunoassay) may be biased by the ratio of compartments
with high IGF-I contents (nuclei, cytoplasm) to those with low
IGF-I contents (extracellular compartment). This ratio varies
considerably between the different categories of smooth muscle
tissues. Immunohistochemicalsemiquantification was restricted to
the cellular compartments. Finally, some variation in loss of
unbound IGFs during immunohistochemical processing cannot be
excluded.
IGF-11 immunostaining was diffuse over both smooth muscle
and stromal cells inmyometrium,leiomyoma andleiomyosarcoma
(Figure 4B) with similar staining intensities in the cellular
compartments of the four categories of smooth muscle tissues
(Figure 3B). The peptide was predominantly found in the cyto-
plasm and seemed to be concentrated in an areaclosely associated
with the nucleus. Results with all three IGF-Il antisera were
similar, apart from a more prominent detection of perinuclear
concentration with the no. 12/2378 antiserum. IGF-11 peptide
levels (RIA) werehigher inleiomyosarcomas than inmyometrium
but, because of ahigh variance inlow-gradeleiomyosarcomas and
the small sample size of intermediate-high-grade leiomyosar-
comas, this has no statistical significance.
Diff-usetype I IGFreceptorimmunostaining was observed in the
cytoplasm of smooth muscle cells in all smooth muscle tissues
(Figure 4Q, with higher intensity in leiomyomas than in
myometrium and leiomyosarcomas (Figure 3B). Immunostaining
for the type II IGF receptor revealed positive staining, also in
smooth muscle cells. Diffuse immunostaining was found over the
cytoplasm (Figure 41)). Staining intensity was similar in
myometrium andleiomyoma, but there was a lowerstaining inten-
sity in most leiomyosarcomas (Figure 3B). IGFBP-3 was visual-
izedbyimmunohistochemistry in thecytoplasm ofsmooth muscle
cells (Figure 4E), with higher intensity in myometrium and
leiomyoma than in leiomyosarcoma (Figure 3B). As for IGF-II,
immunostaining was concentrated in a perinuclear region. The
distribution of staining intensities for both IGF receptors and for
T1"_MD_'A r%,ty,,A-r tha frvivr t;,vcima ixy-ac e;ain;-Sinninflu ti;ffi-ri-nt
from a random distribution.
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Figure 2 In situ hybridization for IGF-11 mRNA, illustrating that thesignal
emerges from smooth muscle cells. Thesignal is diffuse and with low
intensity in myometrium (A); with cell-dependent intensity differences in
leiomyoma (B); diffuse and with high intensity in a low-grade leiomyosarcoma
(C); case B in theTable). Illustrations ofmyometrium and leiomyoma are
representative. Protocol as in Figure 1A; tissue staining with
haematoxylin-eosin. Scale bar = 25 gm
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Figure 3 (A) IGF-I and IGF-ll variables in myometrium (MM), leiomyoma (LM), low-grade leiomyosarcoma (LMS-I) and intermediate- and high-grade
leiomyosarcoma (LMS-ih). Note that all IGF-1l measurements have maximum values in low-grade leiomyosarcomas. Northern blotting scanning values of bands
of IGF-I and IGF-I1 mRNAs, obtained with a densitometer, were corrected for exposure time. These data are a revision of previously obtained results (see
Materials and methods and Gloudemans et al, 1990). In situ hybridization values were obtained by exposure of the hybridized sections to a storage phosphor
screen (see Materials and methods). Radioimmunoassay values represent concentrations in tissue extracts. Northern blotting values and mRNA in situ
hybridization scan values are presented as a percentage relative to the average of the myometrium sections (which was set to 100%). The in situ hybridization
graphs include the residual value after RNAase pretreatment of 11 sections (as controls for RNA hybridization), randomly collected from all four tissue groups
(0, left bar). Radioimmunoassay values represent absolute concentrations. The figure below each group indicates the number of included cases. Error bars
represent standard error of the mean. Significance of differences between groups were calculated using a t-test. *P < 0.05, **P < 0.01. (B) Representation of
immunostaining intensities in the cellular compartments of smooth muscle tissues. From top to bottom, each panel contains myometrium (MM), leiomyoma (LM),
low-grade leiomyosarcomas (LMS-1) and intermediate-high-grade leiomyosarcoma (LMS-i/h); the number of the respective tissues included in each panel is
indicated. The bars show the percentage of tissues staining with the given intensity. These scores are interpreted as ±, absent or low; +, intermediate; and ++,
high. There is a peak level of type I IGF receptor (rec-1) immunostaining in leiomyomas. Immunostaining for IGF-1, type 11 IGF receptor (rec-2), and IGFBP-3
(BP-3) is lower in both groups of leiomyosarcomas than in myometrium and leiomyoma. IGF-11 immunostaining is similar in all four categories of tissues.
Significance of difference between the observed distribution and a random distribution of immunohistochemical staining intensities for each antigen over the four
categories of smooth muscle tissues was analysed in a chi-square test. *P < 0.05, **P < 0.01
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Figure 4 Immunohistochemical detection of IGF-1, IGF-11, type and type 11 IGF receptors and IGFBP-3 on frozen sections. Pictures are representative of the
staining pattems for these antigens, which were similar for each of these antibodies in myometrium, leiomyoma and all grades of leiomyosarcoma. (A) IGF-I
immunostaining with the no. 878/4 antiserum of a leiomyoma, revealing the antigen in the cytoplasm (open arrows) and with higher intensity on the nucleus
(arrowheads). (B) IGF-Il staining (no. C41 antiserum) of a leiomyoma is concentrated in the cytoplasm (open arrows, nuclei are identified with arrowheads). (C)
Type IGF receptor immunostaining with the a-lR3 antibody shows positive staining in the cytoplasm (arrows) of smooth muscle cells of a leiomyoma. (D) Type II
IGF/M6P receptor (no. 3637), detected diffusely in the cytoplasm (arrows) of a myometrium. (E) IGFBP-3 (no. 3596), visualized in the cytoplasm of the smooth
muscle cells of a leiomyoma (open arrows, nuclei are identified with arrowheads). (0), Incubation without a primary antiserum of a myometrium. The
immunoperoxidase DAB/nickel staining shows in various grades of brown/gray. Nuclei are counterstained with nuclear fast red (showing red/pink). All illustrations
are at the same magnification; scale bar = 25 gm in the low-power microphotographs and scale bar = 10 gm in the high-power magnifications (inserts)
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DISCUSSION
IGF production in smooth muscle tissues
The first question of this study addresses the site of production of
IGFs in smooth muscle tissues. In all three categories of smooth
muscle tissues - myometrium, leiomyoma and leiomyosarcoma -
IGF mRNAs were predominantly detected in smooth muscle cells.
This is in line with the distribution of IGF-I mRNA in uterine
smooth muscle cells in rats (Ghahary et al, 1990). Using immuno-
histochemistry, it could be demonstrated that IGF-II in smooth
muscle cells predominantly results from endogenous production,
because it is concentrated in a perinuclear region. Endogenous
production as the major source for IGF-II is further supported by
the concomitant peaks of mRNAs and peptide, as detected with
radioimmunoassay, in low-grade leiomyosarcomas (Figure 3A).
Cytoplasmic staining for IGF-I was more diffuse, compatible with
endogenous production and endocytosis. The importance of
binding and internalization ofIGF-I is supported by concomitantly
higher IGF-I peptide and type I IGF receptor levels in leiomyomas
than in myometrium, without a change in IGF-I mRNA levels.
There are no obvious changes in IGF-I mRNA levels, supporting
IGF-I production.
The hybridization signal for IGF-I and -II mRNAs was found
with equal intensity over all cells in myometrium. This may be a
manifestation of a well-regulated IGF gene expression in this
tissue, for which the oestrogenic cycle may be the regulating prin-
ciple (Ghahary et al, 1990; Murphy, 1991; Kapur et al, 1992;
Stevenson et al, 1994). In contrast, individual cells in leiomyomas
show large differences of IGF mRNA levels, indicating
autonomous production of these mRNAs. Oestrogen-independent
expression in leiomyomas has been reported for both IGF genes
(Giudice et al, 1993; Vollenhoven et al, 1994). Higher IGF-II
mRNA levels in low-grade smooth muscle sarcomas than in
myometrium also indicate autonomous production.
In conclusion, normal and transformed smooth muscle cells can
produce both IGFs in vivo. Additional IGF-I enhances density of
cultured smooth muscle cells (Van der Ven et al, 1994). Thus, the
IGFs may contribute to the stimulation of smooth muscle cell
proliferation in vivo in an auto-paracrine mode of action, which is
a regulated mechanism in normal uterus myometrium but not in
transformed tissues.
Role of IGFs in transformation of smooth muscle
tissues
The second object of this study was to determine the contribution
of the IGF system to transformation and progression of transfor-
mation in smooth muscle tissues. A variable expression of the
components of the IGF system was detected in the different cate-
gories ofnormal and benign smooth muscle tissues.
The higher levels of the type I IGF receptor in leiomyomas
compared with myometrium (Figure 3B) were discussed previ-
ously as a cause for the detected higher IGF-I levels in leiomyoma
compared with myometrium, because ofhigher IGF-I binding and
endocytosis (Van der Ven et al, 1994). Overexpression of type I
IGF receptor may contribute also to transformation. This is
suggested by the occurrence of increased type I IGF receptor
levels in other tumours (Glick et al, 1989; Merrill and Edwards,
1990; Peyrat et al, 1990), representing benign (meningioma) and
malignant tumours (glioma, breast cancer). A direct oncogenic
action ofthe type I IGF receptor was suggested by the induction of
a (ligand-dependent) transformed phenotype in rodent and human
fibroblasts due to overexpression of this receptor (Kaleko et al,
1990; Prager et al, 1994). Conversely, blocking of type I IGF
receptor production resulted in reversal of the transformed pheno-
type of several tumour cell lines (Resnicoff et al, 1994a, b; Long et
al, 1995) and mouse embryo cells without type I IGF receptor are
refractory to transformation by oncogenes (Sell et al, 1993). In
leiomyosarcomas, however, levels of the type I IGF receptor were
similar to those in myometrium, and therefore a possible role for
this receptor in transformation of smooth muscle cells seems to be
restricted to benign transformation.
There was a continuous increase in IGF-II mRNA levels from
myometrium to leiomyoma to low-grade leiomyosarcomas. This
tendency was found with in situ hybridization and with Northern
blot analysis. Higher levels ofIGF-II mRNAs in leiomyomas were
also reported by others (Vollenhoven et al, 1994), and IGF-II over-
expression has also been observed in other tumours (Antoniades et
al, 1992; Macaulay, 1992; Ilvesmaki et al, 1993). In five rhab-
domyosarcomas, IGF-II expression was inversely proportional to
the degree of differentiation (Yun, 1992), but this finding is in
contrast to the lower IGF-II expression in intermediate-high-grade
leiomyosarcomas than in low-grade leiomyosarcomas in our
study. The higher IGF-II expression in low-grade tumours may
indicate a role for IGF-II as a tumour promoter, as was also
suggested by the increased tumour incidence in IGF-II transgenic
mice (Rogler et al, 1994).
Compared with normal smooth muscle tissues, low-grade
leiomyosarcomas show lower expression ofIGF-I mRNA (Northern
blotting), and all leiomyosarcomas show lower immunostaining
intensity for IGF-I, type II IGF receptors and IGFBP-3. This may
reflect a decrease of differentiation of these tumours, as suggested
by the observed decrease of x-SMA (Table) and the reported
decrease of smooth muscle markers associated with dedifferentia-
tion in leiomyosarcomas (Roholl et al, 1988, 1990; Fukuda et al,
1992). Indeed, presence of type II IGF receptor was dependent on
differentiation in other model systems (Cuthbertson et al, 1989;
Szebenyi and Rotwein, 1991; Elliott et al, 1993).
Differences of expression of components of the IGF system
between leiomyomas and leiomyosarcomas are for the most part
not continuous with those between myometrium and leiomyomas.
This may be as a result of differences in origin, because none of
the leiomyosarcomas included in this survey originated from the
uterus, whereas all the leiomyomas did. Uterine leiomyomas are a
particular category with respect to their frequent occurrence,
compared with leiomyomas from other origins, but share cyto-
genetic aberrations with non-uterine leiomyomas (Mark et al,
1991). Smooth muscle cells of uterine and non-uterine (blood
vessels, gastrointestinal tract, lower urinary tract, vagina) origin
share a responsiveness to oestrogen and/or progesterone (Wolf et
al, 1991; Everson, 1992; Karas et al, 1994), although there may be
differences in expression ofreceptors for these hormones between
smooth muscle cells of various parts of one organ. These features
argue for the validity of comparing uterine leiomyomas with
leiomyosarcomas from other origins.
In this comparison, it must be concluded that progressing trans-
formation in smooth muscle tumours is associated with complex
changes involving gain and loss of expression of various compo-
nents of the IGF system. Distinct expression patterns of the IGF
system are associated with different phenotypes of smooth muscle
cell tissues, and therefore it is more likely that transformation to
malignant smooth muscle tumours is not a proceeding process, but
British Journal ofCancer(1997) 75(11), 1631-1640 0 Cancer Research Campaign 1997IGFsystem andsmooth muscle transformation 1639
that each grade of smooth muscle tumour results from a distinct
transformation event. In either case, in this model, the importance
of the IGF system for tumorigenesis seems to be restricted to the
lower grades oftransformation.
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